Nav: Home

For first time, potential treatment path becomes clear for subtype of Charcot-Marie-Tooth disease

November 07, 2019

LA JOLLA, CA - An unexpected finding from the Scripps Research laboratory of Xiang-Lei Yang, PhD, has illuminated a potential strategy for treating the inherited neurological disease Charcot-Marie-Tooth (CMT), for which there is no approved medicine today.

CMT is a progressive disease that typically develops early in life, affecting roughly 1 in 2,500 people. Over time, the disease inflicts damage on patients' peripheral nervous system--which extends from the spinal cord into the hands and feet--often resulting in difficulties with balance, walking and fine motor skills such as writing or buttoning a shirt.

In a study that appears in Nature Communications, Yang and her team show that a drug may be able to prevent the disease-causing mechanisms from occurring within cells, quelling many key symptoms, including motor deficits.

The approach centers on enzymes known as aminoacyl-tRNA synthetases (aaRSs), which are pervasive throughout the body. They are the largest protein family linked to CMT disease, and also the long-running research specialty of Yang's lab. These enzymes are essential to life because they kick off the first step of making new proteins, which are the building blocks of everything from blood and hormones to skin and bones. But in patients with CMT, some of the aaRS enzymes don't function as they should. As a result, peripheral neurons aren't made properly and become toxic to the peripheral nervous system.

In her search for a potential treatment approach, Yang wanted to find out why the mutated enzymes only seem to affect peripheral neurons. She discovered that while aaRS enzymes typically function in a part of the cell known as the cytoplasm, one mutated form of the enzyme known as TyrRS--which is known to be linked to the disease--exists inside a cell's nucleus.

"The nucleus is the site for gene expression or transcription to take place, which made this finding of special interest to us," Yang says. "Transcription regulates the identity of cells and cell-specific maintenance programs, and if something goes awry during this process, disease can result."

Fueled by the excitement of her nucleus discovery, Yang collaborated with Albena Jordanova, PhD, at the University of Antwerp. Jordanova is the scientist who first linked the mutant TyrRS enzyme to CMT disease and established a fruit fly model that exhibits CMT, enabling disease-focused research efforts.

Working together, the teams conducted experiments on fruit flies that showed "unequivocally" that the location of TyrRS in the nucleus was contributing to disease in a significant way. Then, by using a small-molecule drug called embelin to keep the enzyme from entering the nucleus, the team "achieved a complete rescue" of a fruit fly with CMT disease.

Yang noted that the discovery is most immediately relevant for patients who have a form of the disease known to be caused by mutant TyrRS. However, the findings may translate to subtypes caused by other mutant aaRSs enzymes.

"This work paves the way for developing a viable therapy for CMT patients affected by TyrRS mutations," Yang says. "We're excited to advance this research by further validating the therapeutic approach and finding the best-possible pharmaceutical product to inhibit this enzyme from entering the nucleus. We also will investigate whether the nuclear relevance can be generalized to other CMT subtypes."
-end-
Authors of the study, "Transcriptional dysregulation by a nucleus-localized aminoacyl-tRNA synthetase associated with Charcot-Marie-Tooth neuropathy," are Sven Bervoets, Na Wei, Maria-Luise Erfurth, Shazie Yusein-Myashkova, Biljana Ermanoska, Ligia Mateiu, Bob Asselbergh, David Blocquel, Priyanka Kakad, Tyrone Penserga, Florian P. Thomas, Velina Guergueltcheva, Ivailo Tournev, Tanja Godenschwege, Albena Jordanova and Xiang-Lei Yang.

The study was supported in part by the National Institutes of Health (NS085092; 2013-2018) and by a fellowship from National Foundation for Cancer Research.

Scripps Research Institute

Related Enzymes Articles:

How nature builds hydrogen-producing enzymes
A team from Ruhr-Universität Bochum and the University of Oxford has discovered how hydrogen-producing enzymes, called hydrogenases, are activated during their biosynthesis.
New family on the block: A novel group of glycosidic enzymes
A group of researchers from Japan has recently discovered a novel enzyme from a soil fungus.
Surprising enzymes found in giant ocean viruses
A new study led by researchers at Woods Hole Oceanographic Institution (WHOI) and Swansea University Medical School furthers our knowledge of viruses -- in the sea and on land -- and their potential to cause life-threatening illnesses.
How host-cell enzymes combat the coronavirus
Host-cell enzymes called PARP12 and PARP14 are important for inhibiting mutant forms of a coronavirus, according to a study published May 16 in the open-access journal PLOS Pathogens by Stanley Perlman of the University of Iowa, Anthony Fehr of the University of Kansas, and colleagues.
New method enables 'photographing' of enzymes
Scientists at the University of Bonn have developed a method with which an enzyme at work can be 'photographed'.
Everyday enzymes, now grown in plants
Whether we know it or not, enzymes play a role in a range of everyday products, from orange juice to denim jeans.
Balance of two enzymes linked to pancreatic cancer survival
UC San Diego School of Medicine research sets the stage for clinicians to potentially one day use levels of a pancreatic cancer patient's PHLPP1 and PKC enzymes as a prognostic, and for researchers to develop new therapeutic drugs that inhibit PHLPP1 and boost PKC as a means to treat the disease.
Biologists have studied enzymes that help wheat to fight fungi
Scientists from I.M. Sechenov First Moscow State Medical University together with their Russian colleagues studied reaction of wheat plants to damage caused by pathogenic fungi.
Scientists developed enzymes with remote control
Scientists developed a method to enhance the activity of enzymes by using radio frequency radiation.
Enzymes in the cross-hairs
More and more bacteria are resistant to available antibiotics. A team of chemists from the Technical University of Munich now presents a new approach: they have identified important enzymes in the metabolism of staphylococci.
More Enzymes News and Enzymes Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

Risk
Why do we revere risk-takers, even when their actions terrify us? Why are some better at taking risks than others? This hour, TED speakers explore the alluring, dangerous, and calculated sides of risk. Guests include professional rock climber Alex Honnold, economist Mariana Mazzucato, psychology researcher Kashfia Rahman, structural engineer and bridge designer Ian Firth, and risk intelligence expert Dylan Evans.
Now Playing: Science for the People

#540 Specialize? Or Generalize?
Ever been called a "jack of all trades, master of none"? The world loves to elevate specialists, people who drill deep into a single topic. Those people are great. But there's a place for generalists too, argues David Epstein. Jacks of all trades are often more successful than specialists. And he's got science to back it up. We talk with Epstein about his latest book, "Range: Why Generalists Triumph in a Specialized World".
Now Playing: Radiolab

Dolly Parton's America: Neon Moss
Today on Radiolab, we're bringing you the fourth episode of Jad's special series, Dolly Parton's America. In this episode, Jad goes back up the mountain to visit Dolly's actual Tennessee mountain home, where she tells stories about her first trips out of the holler. Back on the mountaintop, standing under the rain by the Little Pigeon River, the trip triggers memories of Jad's first visit to his father's childhood home, and opens the gateway to dizzying stories of music and migration. Support Radiolab today at Radiolab.org/donate.